You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Rheumatic diseases in intensive care unit patients with COVID-19
  1. Sergey Moiseev1,
  2. Sergey Avdeev2,
  3. Michail Brovko1,
  4. Andrey Yavorovskiy3,
  5. Pavel I Novikov1,
  6. Karina Umbetova4,
  7. Larisa Akulkina1,
  8. Natal'ya Tsareva2,
  9. Victor Fomin5
  1. 1 Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  2. 2 Clinic of Pulmonology, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  3. 3 Clinic of Intensive Care, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  4. 4 Clinic of Infectious Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  5. 5 Vinogradov Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  1. Correspondence to Professor Sergey Moiseev, Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow 119435, Russian Federation; avt420034{at}yahoo.com

https://doi.org/10.1136/annrheumdis-2020-217676

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Patients with autoimmune rheumatic diseases have an increased risk of viral infections that can be attributed to the underlying immunological abnormalities, comorbidities and immunosuppressive therapy. Moreover, immunocompromised patients with influenza had more severe disease, longer viral shedding and more antiviral resistance while demonstrating less clinical symptoms and signs.1 COVID-19 in patients with autoimmune rheumatic diseases, particularly treated with immunosuppressive agents, is also likely to follow the deleterious course previously reported in the other respiratory viral infections.2

    Surprisingly, little is known about the association of COVID-19 and inflammatory rheumatic diseases, although the number of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already exceeded two millions and continues to rise in many countries, including Russia. In a recent article, Monti et al suggested that patients with chronic arthritis treated with biological and targeted synthetic disease modifying antirheumatic drugs (DMARDs) do not seem to be at increased risk of respiratory or life-threatening complications from COVID-19 compared with the general population.3 However, more data about the prevalence, severity and outcomes of COVID-19 in patients with rheumatic disease are urgently needed to identify patients at …

    View Full Text

    Footnotes

    • Contributors All authors contributed to the manuscript.

    • Funding The Russian Academic Excellence Project 5–100.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles